<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>152</td>
<td>Expression profile of circRNA in peripheral blood mononuclear cells of patients with Parkinson’s disease and atypical parkinsonian syndromes</td>
</tr>
<tr>
<td>153</td>
<td>Exosomal α-synuclein in Multiple system atrophy and parkinson’s disease cause distinct synucleinopathies</td>
</tr>
<tr>
<td>154</td>
<td>In vivo proteomic investigation of deeply phenotyped parkinsonian syndromes for biomarkers of differential diagnosis</td>
</tr>
<tr>
<td>155</td>
<td>Analysis of the therapeutic potential of c-Abl inhibition in Multiple System Atrophy</td>
</tr>
<tr>
<td>187</td>
<td>A tau-directed monoclonal antibody could alter the tau pathology of progressive supranuclear palsy</td>
</tr>
<tr>
<td>188</td>
<td>Evaluation of a novel Phosphodiesterase 5 inhibitor as a potential therapeutic agent in P301S transgenic mouse model of tauopathy.</td>
</tr>
<tr>
<td>189</td>
<td>Introducing the molecular subtyping of Progressive Supranuclear Palsy: a proof of concept</td>
</tr>
<tr>
<td>237</td>
<td>A vicious cycle of karyopherin abnormalities in synucleinopathies</td>
</tr>
<tr>
<td>269</td>
<td>Analysis of the network of genes related to Parkinson’s and identification of key proteins</td>
</tr>
<tr>
<td>270</td>
<td>Transcriptional dysregulation in iPSC-derived neurons from patients with X-linked dystonia-parkinsonism</td>
</tr>
<tr>
<td>339</td>
<td>Protective effect and mechanism of TREM2 in Parkinson's disease with cognitive impairment</td>
</tr>
<tr>
<td>403</td>
<td>Effects of Eromomastax speciosa in a Gastric Ulcer in a 6-hydroxydopamine (6-OHDA)-induced Rat Model of Parkinson's Disease.</td>
</tr>
<tr>
<td>404</td>
<td>Ramelteon ameliorates abnormal sleep-wake behavior in a zebrafish model of Parkinson's disease by facilitating abnormal lipid metabolism</td>
</tr>
<tr>
<td>593</td>
<td>Tramadol Induces Neuroinflammation, Mitochondrial Oxidative Stress, Neurotransmitters Dysbalanced and Produced Parkinson’s Disease Like Symptoms in Experimental Wistar Rats</td>
</tr>
<tr>
<td>594</td>
<td>Quercetin hinders Glial Activation to Alleviate the Cadmium Induced Dopaminergic Alteration via TNFα mediated CAMKIIα/ERK activation</td>
</tr>
<tr>
<td>595</td>
<td>Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson's disease</td>
</tr>
<tr>
<td>596</td>
<td>The comparison of curcumin and naringenin effects on motor function in rotenone model of Parkinson's disease</td>
</tr>
<tr>
<td>597</td>
<td>Hesperidin ameliorates rotenone-induced Parkinson’s disease in mice via improving neuroinflammation and oxidative stress</td>
</tr>
<tr>
<td>676</td>
<td>The neuroprotective miRNA family hsa-miR-451 has a distinctive pattern of downregulation in neurodegenerative diseases.</td>
</tr>
<tr>
<td>742</td>
<td>Calcium phenotype in cellular models of VPS13A disease</td>
</tr>
</tbody>
</table>
Disorder of bulk lipid transfer? Lipid composition and distribution in cellular models of VPS13A disease

Transcriptomic profiling in DYT1 dystonia: unravelling pathogenic pathways.

Exploring the effects of torsinA dysfunction in an iPSC-derived neuronal model of TOR1A dystonia

AAV5-miHTT gene therapy mediates sustained mutant huntingtin lowering in brain and cerebrospinal fluid of Huntington’s disease minipigs up to 5 years

Effects of a small molecule angiotensin IV analog on Huntington's disease animal model

Stiff-Person Syndrome: Diagnosis and Experimental Models

Anti-tremor efficacy of Nabiximols (JZP378) in a rat Model of essential tremor

Frequency coding mechanism of tremor in the cerebellar circuitry

Mosaic divergent repeat interruptions in X-linked dystonia-parkinsonism: stability over generations and time

Impacts of mutations in Parkinson’s disease-related genes on telomere maintenance

Transcriptome-microRNA correlation and the regulation of targeted gene expression in de novo Parkinson’s disease patients.

The role of RNA-carrying exosomes in synaptic physiology and in synucleinopathies

Genome Wide Association Studies using TRACTOR reveals new associated loci with Parkinson Disease in a Latino Cohort

Uncovering the mechanisms of genotype by environment interaction in an idiopathic Parkinson's disease model in Drosophila

The development of a multiplex allele specific PCR to improve the diagnostic yield of NGS in the GBA gene screening

Evaluation of small extracellular vesicles derived miRNA as biomarkers for Parkinson's disease: comparison with plasma miRNA

Genome-wide association identifies novel etiological insights associated with Parkinson’s Disease in African and African admixed populations

Epigenome-wide meta-analysis of sex-differential DNA methylation in Parkinson’s disease

Conventional anti-epileptic drugs used in North Sea Progressive Myoclonus Epilepsy revisited in a Drosophila model

In vitro α-synuclein aggregation and propagation model

Alterations in Cortico-basal ganglia Directed Connectivity in Parkinsonism and during Therapeutic STN DBS
1195 Representation of movement repertoire in subthalamic neural circuits using a markerless 3D behavioral tracking system.

1196 The changes in alpha-synuclein level and oscillatory activity of substantia nigra by nigral electrical stimulation

1246 Pathological neuronal Oscillations in an animal model of Rapid-Onset Dystonia-Parkinsonism

1249 Evoking Parkinsonism in Mice by a Pharmacological Approach Combined with Targeted Viral-based Manipulations of Neuronal Ensembles

1250 Dopaminergic Neuronal attributes in aging Substantia Nigra and Ventral Tegmental Area of mice strains distinctly sensitive to MPTP

1251 A human tissue engineered nigrostriatal system as a testbed for understanding PD pathophysiology and therapeutic development

1252 Decreased α-synuclein membrane-binding in the enteric nervous system as a marker of early pathology in Parkinson's disease

1253 The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson's disease

1255 Axon terminal hypertrophy of striatal projection neurons with levodopa-induced dyskinesia priming

1256 IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with synucleinopathy

1329 Characterisation of the pharmacokinetic profile of L-DOPA in the common marmoset

1330 Effect of ADX-88178, a highly-selective mGlu4 PAM, on parkinsonism, dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset

1333 Effect of the 5-HT2A/2C inverse agonist nelotanserin on dyskinesia in the MPTP-lesioned marmoset

1334 Quantitative investigation of the pathway between dopamine receptors and Ca2+ channels in layer II stellate cells towards Parkinson's disease

1336 Polyaromatic hydrocarbons in Ambient Particulate Matter (PM 2.5) mediate neurodegeneration through the olfactory-brain axis in C57BL/6 mice

1337 The neuroprotective properties of NLX-112 in MPTP treated mice are mediated by reactive gliosis and astrocytic GDNF

1344 The induction of mitochondrial damage by alpha synuclein In Parkinson's disease.

1346 Identification of ZYIL1, a novel NLR family pyrin domain containing 3 protein inhibitor: a potential disease modifier in Parkinson's disorder

1347 Glucocerebrosidase (GCase) activator, Ambroxol, reduces alpha-synuclein serine-129 phosphorylation and oligomers in mutant LRRK2 R1441G mouse brains

1348 Evaluation of neuroprotective role of carvacrol via Nrf2-NLRP3 axis in rotenone induced PD mice model
1350  
Thymoquinone and Edible Bird Nest: The Secret Ingredients to Protect Against MPTP-induced zebrafish Parkinson's disease

1351  
Therapeutic effects of citral nanoliposome on Parkinson's treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways

1352  
Identification of xylopropamine as a potential dopamine D2 receptor agonist through computational drug discovery pipeline

1353  
Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson's disease in a marmoset monkey model

1354  
The mGlu2 positive allosteric modulator AZD8529 alleviates L-DOPA-induced dyskinesia and psychosis-like behaviours in the parkinsonian marmoset

1357  
Modulation of sodium potassium ATPase activity by norepinephrine and serotonin to find an effective cure of parkinson's disease by introducing the novel concept of insilico drug repurposing

1358  
Honey prevented MPTP-induced oxidative stress, neuroinflammation and gliosis in adult male Swiss mice.

1359  
Glunomab: a novel therapeutics for the treatment of Parkinson's Disease

1360  
LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte-derived macrophages and SH-SY5Y

1361  
Investigation of superficial brain stimulation (SBS) in Parkinsonian rats as a non-invasive alternative treatment for patients with movement disorders

1362  
Development of therapeutic substances for the disassembly of α-synuclein aggregates as disease-modifying treatment of synucleinopathies

1363  
Effect and Mechanism of Shaoyao Gancao Decoction(SGD) in Treatment of Pain in Parkinson's Disease Based on Network Pharmacology and Molecular Docking

1362  
Metabolic modulation of mitochondrial DNA release in cellular models of Parkin-associated Parkinson's disease

1452  
miRNAs from blood serum as an early diagnostic biomarker for Parkinson's disease: A study in an animal model

1453  
Sub-cellular alterations in MPTP-induced in-vivo and in-vitro systems and Non-MPTP human Parkinsonian skin biopsies: Verifying the sequelae of differential toxicity

1455  
LRRK2 G2019S as a trigger of inflammatory signaling in patient-derived microglia

1456  
Inhibition of LRRK2 kinase activity promotes glucocerebrosidase transport to the lysosomes in primary monocyte-derived macrophages from patients with GBA-associated Parkinson's disease

1457  
SLP-2 modulated expression rescues mitochondrial function in alpha-synuclein neuropathology models
Impaired CaMKII/ERK activation in mouse mutant LRRK2 R1441G fibroblasts was associated with reduced mitochondrial calcium store and efflux in response to depolarization stress.

Glycated alpha-synuclein and its emerging role in early onset of Parkinson's disease.

SARS-CoV-2 infection exacerbates the cellular pathology in Parkinson's disease progression.

Small Molecule Inhibitors for Precise Inhibition of α-Synuclein Oligomer Generation in Parkinson's Disease (PD).

Impairment of SHH signaling in PD LRRK2 I1371V iPSC derived floor plate cells contribute to ontogenic origin of lower dopaminergic-neuron yield.

Exploring mitochondrial mechanisms defining Parkinson's disease penetrance in LRRK2 G2019S neuronal cultures.


Parkin Coregulates Glutathione Metabolism in Adult Brain to Contribute to Redox Homeostasis.

Proteomic profiles analysis of plasma exosomes and WBC reveals new insights of PD patients classified into H&Y clinical stage.

A novel, population-specific PINK1 p.F385S loss of function mutation in an Indian family with Parkinson's disease.

Novel modifiers of heterozygous pathogenic Parkin variant penetrance in Parkinson's disease.

Membrane-associated properties and ER stress alterations in LRRK2 I1371V patient iPSC derived neurons increase susceptibility to oxidative stress.

Targeting autophagy to identify novel modulators of Parkinson's disease using midbrain organoids.

The Role of Adaptive Immunity caused by α-synuclein Recognition Specific Sequence Peptide on the Onset of Parkinson's Disease Pathogenesis.

Selenium mitigates ferroptosis-mediated dopaminergic cell death by regulating the Nrf2/GPX4 pathway: Implication for Parkinson's disease.

Impaired lysophagy function exacerbates propagation of α-synuclein aggregation.

Modulation of autophagy and neuroinflammation by Niclosamide in MPTP Induced Parkinson's disease model.

Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia.

Hypoxia-induced astrocyte activation and its protective effect on Parkinson's disease.

LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α-synuclein through NF-κB pathway.
Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson's disease

Identification of reproducible metabolites for Parkinson's Disease diagnosis using clinical data and computational modelling

Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's Disease mouse model

Selegiline drives autophagic secretion of alpha-synuclein

Distinct temporal and spatial alteration of immunoproteasome in Parkinson's Disease pathogenesis

Impaired Mitophagy and Mitochondrial-energetics in Parkinson's disease: A Novel Therapeutic Strategy of Re-tasking Felodipine

Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?


Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson's Disease

RNA editing contributes to the inflammatory astrocytic response in Parkinson's disease.

TREM2 maintain microglial proliferation and alpha-syn accumulation in PD models via the PI3K-Akt pathway

The N6-Methyladenosine mRNA Methylase METTL14 Regulates TLR4-mediated intestinal dysfunction in Parkinson's Disease

Characterizing the neural response to electrical brain stimulation with spatiotemporal precision in mice.

Estrogen and progesterone influence membrane functions and glucose transporter expression in synaptosomes of different age groups of naturally menopausal rats

Role of nanoparticles of berberine on oxidative stress in nigrostriatal tissue and neurobehavioral characteristics in rotenone induced animal model of Parkinson's disease

Age-associated changes in the striatal proteins in aging Asian-Indians

The effect of anti-Parkinson's disease granules and probiotics on gastrointestinal motility in the mouse model of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine -induced Parkinson's disease